Lung Cancer

Despite its benefits, data suggest that comprehensive molecular testing in patients with non-small cell lung cancer is underutilized due to a lack of resources.

Exposure to household air pollutants, especially solid fuel, appeared linked to lung cancer death among individuals who have never smoked, according to a study published in American Journal of Respiratory and Critical Care Medicine.

2022 has brought many research updates and approvals in lung cancer.

The FDA issued a complete response letter to Spectrum Pharmaceuticals indicating it could not approve the company’s new drug application that sought approval of poziotinib as treatment for certain patients with lung cancer.

Precision medicine has shown great potential to improve treatment outcomes and prolong survival of patients with lung cancer, as biomarker-driven therapies continue to extend their reach in this space.

The arthrobacter luteus/albumin ratio demonstrated a strong dose-response relationship with overall lung cancer risk and may be helpful in identifying individuals who should undergo screening, according to study results published in Chest.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

Less than 6% of eligible Americans have undergone lung cancer screening, according to American Lung Association’s 2022 State of Lung Cancer report.

New treatments for emerging targets have expanded the armamentarium in lung cancer, according to a speaker at Chemotherapy Foundation Symposium.

The FDA approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for certain patients with metastatic non-small cell lung cancer.